NCT07090330Phase 2Active not recruiting

ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis

Study sponsor: Oruka Therapeutics, Inc. · ORKA

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2026-03-25Actual

Enrollment · participants80Estimated

Source updated2026-07-01Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-07-01 · 2 fields changed

Completion date type changed

− Before

~~Estimated~~

+ After

Actual

Primary completion date changed

− Before

~~Apr 2026~~

+ After

25 Mar 2026

Check registry source

Posted 2026-03-17 · 2 fields changed

Primary completion date changed

− Before

~~Sep 2026~~

+ After

Apr 2026

Recruitment status changed

− Before

~~Recruiting~~

+ After

Active not recruiting

Check registry source

Study details

Conditions studied

Plaque Psoriasis

Treatments or interventions studied

ORKA-001 Induction DoseDrug
ORKA-001 Maintenance DoseDrug

Primary outcomes · main study measures

measure: Proportion of Participants Achieving 100% Reduction in PASI Score at Week 16; description: The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).; timeFrame: Week 16

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history